 Yahoo! News (blog) |
UK health cost body backs Novartis asthma drug in fresh U-turn
Yahoo! News (blog) LONDON (Reuters) – Britain's health cost-effectiveness watchdog NICE said it planned to recommend the use of Novartis's severe asthma drug Xolair after prevaricating for months over whether it should be paid for on the taxpayer-funded National Health … U-turn As Asthma Drug Gets Go-ahead NICE U-turn over asthma drug omalizumab |
View full post on asthma – Google News